Siegfried Holding AG (SGFEF)
| Market Cap | 4.49B -7.5% |
| Revenue (ttm) | 1.67B +2.6% |
| Net Income | 212.70M +5.4% |
| EPS | 4.84 +4.1% |
| Shares Out | n/a |
| PE Ratio | 21.12 |
| Forward PE | 19.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Average Volume | 234 |
| Open | 1,001.00 |
| Previous Close | 100.00 |
| Day's Range | 100.00 - 1,001.00 |
| 52-Week Range | 100.00 - 1,025.00 |
| Beta | 0.77 |
| RSI | 35.92 |
| Earnings Date | Aug 21, 2026 |
About Siegfried Holding AG
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition,... [Read more]
Financial Performance
In 2025, Siegfried Holding AG's revenue was 1.33 billion, an increase of 2.57% compared to the previous year's 1.29 billion. Earnings were 168.66 million, an increase of 5.37%.
Financial numbers in CHF Financial StatementsNews
SK Capital Partners Completes Sale of Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AG
NEW YORK--(BUSINESS WIRE)--Affiliates of funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the life sciences, specialty materials, and ingredients sectors a...
Siegfried Holding AG Earnings Call Transcript: H2 2025
Record profitability and margin expansion achieved in 2025, with 4.3% sales growth in local currency and strong cash generation. Strategic acquisitions and robust project inflow support a positive midterm outlook, despite currency headwinds and a pending large contract.
Siegfried Holding AG Transcript: M&A announcement
The acquisition of three sites in the U.S. and Australia expands manufacturing capacity, strengthens supply chain resilience, and positions the company for growth in high-demand drug substance markets. The deal is value-accretive, margin accretive, and enables rapid integration with minimal CapEx.
Siegfried Holding AG Earnings Call Transcript: H1 2025
Solid H1 2025 results with 1.6% local currency sales growth, EBITDA margin up to 21.6%, and strong cash flow from networking capital optimization. Full-year guidance confirmed, with continued investment in technology, capacity, and selective M&A to drive above-market growth.
Siegfried Holding AG Earnings Call Transcript: H2 2024
Strong 2024 results with 8%-9% underlying growth, Core EBITDA margin above 22%, and 24% higher Core Net Profit. 2025 guidance targets mid-single-digit growth and continued margin expansion, with robust segment performance, ongoing M&A, and major capacity investments.
Siegfried Holding AG Transcript: CMD 2024
EVOLVE+ strategy focuses on technology expansion, operational excellence, and tailored commercial approaches, driving profitable growth and resilience. Financial guidance confirms continued margin improvement and strong cash generation, with sustainability and digitalization as key value drivers.
Siegfried Holding AG Earnings Call Transcript: H1 2024
Net sales grew 3.5% in local currencies and core net profit rose 21.8% in H1 2024, with profitability and cash flow both improving. Strategic acquisitions and capacity expansions support a positive outlook, with guidance reaffirmed for low single-digit sales growth and stable margins.